Literature DB >> 19143068

Magnetic resonance imaging findings of tamoxifen-associated uterine Müllerian adenosarcoma: a case report.

E Soh1, A Eleti, M Jimenez-Linan, M J Arends, J Latimer, E Sala.   

Abstract

Müllerian adenosarcoma of the uterus is a rare biphasic tumor, which was first described in 1974. Recent studies have suggested an association with tamoxifen therapy, but there have been few reports with detailed imaging findings. We present a case with magnetic resonance imaging (MRI) findings of this rare tumor in a woman who received long-term tamoxifen therapy for breast cancer. In addition, myometrial invasion was detected more accurately with MRI compared to ultrasound in this one single case.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19143068

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  4 in total

Review 1.  Uterine Adenosarcoma: a Review.

Authors:  Michael J Nathenson; Vinod Ravi; Nicole Fleming; Wei-Lien Wang; Anthony Conley
Journal:  Curr Oncol Rep       Date:  2016-11       Impact factor: 5.075

Review 2.  Benign and malignant tumor of the uterine body with broccoli sign: MR imaging features for differential diagnosis.

Authors:  Eito Kozawa; Masahiro Takahashi; Shiori Meguro; Masanori Yasuda; Norihiro Iwasa; Keiichi Fujiwara; Fumiko Kimura
Journal:  Jpn J Radiol       Date:  2013-05-30       Impact factor: 2.374

3.  Mullerian adenosarcoma of the uterus associated with tamoxifen treatment for breast cancer.

Authors:  Yasin Ceylan; Emek Doğer; Ahmet Yiğit Çakıroğlu; Çiğdem Vural; İzzet Yücesoy
Journal:  Turk J Obstet Gynecol       Date:  2015-12-15

4.  Imaging findings of uterine adenosarcoma with sarcomatous overgrowth: two case reports, emphasizing restricted diffusion on diffusion weighted imaging.

Authors:  Go Nakai; Hiroki Matsutani; Takashi Yamada; Masahide Ohmichi; Kazuhiro Yamamoto; Keigo Osuga
Journal:  BMC Womens Health       Date:  2021-12-16       Impact factor: 2.809

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.